Your browser doesn't support javascript.
loading
Utility of silver birch and house dust mite extracts derived from licensed sublingual tablets for nasal allergen challenge.
Olivieri, Bianca; Gil, Ana Jimenez; Stoenchev, Kostadin; Durham, Stephen R; Scadding, Guy.
Afiliación
  • Olivieri B; Asthma, Allergy and Clinical Immunology Section, University Hospital of Verona, Verona, Italy.
  • Gil AJ; Department of Allergy, Royal Brompton & Harefield Hospitals NHS Trust, London, UK.
  • Stoenchev K; Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, UK.
  • Durham SR; Department of Allergy, Royal Brompton & Harefield Hospitals NHS Trust, London, UK.
  • Scadding G; Department of Allergy, Royal Brompton & Harefield Hospitals NHS Trust, London, UK.
Clin Transl Allergy ; 14(5): e12360, 2024 May.
Article en En | MEDLINE | ID: mdl-38779783
ABSTRACT

BACKGROUND:

Nasal allergen challenge (NAC) is used to investigate the effects of allergen exposure and assess treatment efficacy in allergic rhinitis (AR). This study aims to establish dose-responses to NAC using licensed silver birch (SB) pollen and house dust mite (HDM) sublingual tablets as sources of the allergen extracts in participants with AR.

METHODS:

Sixteen volunteers with HDM-induced perennial AR and 15 volunteers with SB pollen-induced seasonal rhinitis underwent a graded up-dosing NAC with extracts derived from HDM allergen (Acarizax®) and SB (Itulazax®) tablets, respectively. Total nasal symptom score (TNSS, range 0-12) and peak nasal inspiratory flow (PNIF) were recorded before, at 10 min and at the end of the NAC. The dose of each allergen that provoked a TNSS of at least 7 ("provoking dose 7") in most allergic participants was identified. NACs using the "provoking dose 7" were performed on 5 non-allergic individuals to test for irritant effects. The "provoking dose 7" of HDM extract was used in a subgroup of two SB allergic, non-HDM allergic, volunteers, and vice versa for SB extract, to test for allergen specificity of the responses.

RESULTS:

Most patients experienced a TNSS of at least 7/12 at a median concentration of 1500 AU/mL for both SB pollen and HDM. The average decline in PNIF at this dose was 63.15% for SB and 63.99% for HDM. NACs using the 1500 AU/mL concentrations were performed on 5 non-allergic individuals with no symptomatic or PNIF response. 1500 AU/mL of HDM extract produced no symptoms in SB allergics nor 1500 AU/mL SB extract in HDM allergics.

CONCLUSION:

For both SB and HDM extracts, the optimal allergen dose for NAC to cause a moderate-severity response ("provoking dose 7/12") was 1500 AU/mL. Licensed sublingual allergen tablets provide a readily available and inexpensive source of SB and HDM extracts for use in future interventional studies in AR.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Transl Allergy Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Transl Allergy Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido